Physician profile
Joel N Hersch
NPI 1831224708
$1,635.72
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $365 · 2021: $269 · 2022: $231 · 2023: $68.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $467.00 | 2019-2022 | |
| Optovue, INC. | $270.53 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $208.05 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $121.87 | 2020 | |
| Kala Pharmaceuticals, INC. | $115.06 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $104.80 | 2019 | |
| Alcon Vision LLC | $90.64 | 2021-2022 | |
| Topcon Healthcare, INC. | $68.18 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Hersch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.